New research reveals how chronically high insulin levels—driven by obesity and diet—act as a direct trigger for pancreatic cancer, offering a powerful new opportunity for prevention.
🎧 ▶️ Press the play button below to listen in English.
🎧 ▶️ 请按下面的播放按钮收听英文音频。
A Devastating Diagnosis: Why Pancreatic Cancer is Often Found Too Late
Pancreatic cancer is a formidable foe. It’s one of the deadliest cancers, often diagnosed at a late stage when treatment options are limited. Its incidence has been rising in recent years, and it is projected to become the second leading cause of cancer death by 2030.[1]
For decades, scientists have known that obesity and type 2 diabetes significantly increase a person’s risk of developing this disease. But what is the biological mechanism behind this link?
A groundbreaking new study from the University of British Columbia has uncovered a crucial piece of the puzzle. The answer, it turns out, may lie in a common but often overlooked condition: hyperinsulinemia, or chronically elevated insulin levels in the blood.
The research, published in the journal Cell Metabolism, reveals that excess insulin acts directly on pancreatic cells, kickstarting the process that can lead to cancer. This discovery not only explains the connection between obesity and pancreatic cancer but also opens the door to potential new prevention strategies.
A Silent Epidemic: What is Hyperinsulinemia?
To understand this finding, we first need to understand insulin’s role in the body. Insulin is a vital hormone produced by the pancreas. Its primary job is to act like a key, unlocking our cells to allow sugar (glucose) from the bloodstream to enter and be used for energy.
In our modern world, where diets are often rich in processed foods and sugar, our bodies can become less responsive to insulin—a condition known as insulin resistance. To compensate, the pancreas works overtime, pumping out more and more insulin to keep blood sugar levels in check. The result is hyperinsulinemia: abnormally high levels of insulin circulating in the blood.
Hyperinsulinemia is a hallmark of obesity and a precursor to type 2 diabetes. It’s incredibly common, affecting an estimated one in three adults in the United States. While often discussed in the context of metabolic health, this new research shows its reach may extend far beyond, acting as a silent driver for one of the most aggressive forms of cancer.
The Pancreas: A Tale of Two Functions
The pancreas is a unique organ with two distinct jobs. Its “endocrine” function, which we just discussed, involves producing hormones like insulin to regulate blood sugar. Its “exocrine” function, which makes up the vast majority of the organ, involves producing and secreting powerful digestive enzymes. These enzymes are essential for breaking down the food we eat, especially fats.
The study, led by researchers Anni M.Y. Zhang, James D. Johnson, and Janel L. Kopp, focused on this exocrine part of the pancreas. The cells responsible for making these digestive enzymes are called acinar cells. And it is in these cells that pancreatic cancer most often begins.
The process typically starts when a normal acinar cell transforms, first into a more duct-like cell (a process called acinar-to-ductal metaplasia, or ADM), and then into pre-cancerous lesions known as PanINs (pancreatic intraepithelial neoplasia), which can eventually progress to full-blown pancreatic ductal adenocarcinoma (PDAC).
The question was: How does a state of high insulin—which is meant to control blood sugar—trigger this dangerous transformation in the exocrine pancreas?
A Direct Link: Insulin Receptors as the Master Switch
The researchers used a sophisticated mouse model to answer this question. They engineered mice that were predisposed to develop pancreatic cancer, carrying a common cancer-driving mutation in the Kras gene (found in over 95% of human pancreatic cancers). These mice were also fed a high-fat diet to make them obese and hyperinsulinemic, mimicking the human condition.
The key part of the experiment was that they could genetically remove the insulin receptor (Insr) from the acinar cells in some of these mice. The insulin receptor is the “lock” on the cell surface that insulin must bind to in order to exert its effects. Without it, the cell becomes deaf to the hormone’s signals.
The results were striking. In mice that had intact insulin receptors on their acinar cells, the high-fat diet led to the rapid development of PanINs and tumors. Their pancreata were ravaged, with healthy tissue replaced by pre-cancerous lesions.
But in mice lacking the insulin receptor specifically in their acinar cells, the story was completely different. Despite eating the same high-fat diet and having the same Kras mutation, these mice showed a dramatic reduction in PanIN formation. Their pancreata remained largely healthy, with much of the normal tissue preserved.
This was the first clear evidence that hyperinsulinemia acts directly on acinar cells via their insulin receptors to initiate pancreatic cancer.
The Mechanistic Chain Reaction: From Enzyme Overload to Inflammation
So, how does insulin binding to its receptor on an acinar cell trigger a path toward cancer? The study’s deep dive into the cellular machinery—using advanced technologies to analyze proteins and their activity (proteomics and phosphoproteomics)—uncovered a fascinating chain reaction.
Insulin’s primary function in acinar cells is not to control blood sugar, but to support their main job: producing digestive enzymes. The researchers found that high insulin levels act like a factory foreman, driving acinar cells to massively ramp up production of these powerful proteins.
This overproduction comes with a major risk. One of the first digestive enzymes produced is trypsinogen, the inactive precursor to trypsin. In a healthy pancreas, these enzymes are safely packaged into granules and released into the gut. But when produced in excess, some trypsinogen can become prematurely activated inside the pancreas.
Activated trypsin is a potent enzyme that starts to digest the very tissue that made it. This causes low-grade, subclinical inflammation—a simmering fire that damages the pancreas without causing the acute pain of full-blown pancreatitis.
This inflammation is the critical second step. In the presence of a Kras mutation (or other cellular vulnerabilities), this constant, low-level injury creates a wound-healing response gone wrong. The damaged acinar cells begin to change their identity, undergoing acinar-to-ductal metaplasia (ADM), the first step toward cancer.
The inflammation also recruits immune cells and creates a “pro-tumor” environment, further fueling the process.
The researchers proved this link in the lab. When they isolated acinar cells and cultured them in 3D, they found that adding insulin dramatically increased the formation of ADM structures. Remarkably, this effect was completely blocked by adding a trypsin inhibitor—a drug that prevents trypsin from becoming active. This confirmed that insulin-driven cancer initiation is dependent on the overproduction and activation of digestive enzymes.
Hope for Prevention: A Clinically Actionable Pathway
The implications of this research are profound. It moves us beyond a simple association between obesity and cancer to a clear, mechanistic understanding of how they are connected.
Crucially, the study offers a beacon of hope. The driver of this pathway—hyperinsulinemia—is not an abstract genetic destiny. It is a condition that is profoundly clinically actionable. This means it can be measured, monitored, and modified.
The main ways to lower insulin levels are lifestyle-based: a healthy diet low in processed carbohydrates and sugars, regular exercise, and maintaining a healthy weight. These are already the cornerstones of preventing diabetes and heart disease. This study adds a powerful new reason to prioritize them: they may be a direct form of cancer prevention.
Furthermore, there are FDA-approved medications that can lower insulin levels, such as metformin (a common diabetes drug). The study’s findings suggest that such drugs, or other strategies aimed at reducing hyperinsulinemia, could one day be used to lower pancreatic cancer risk in high-risk populations.
While the study was conducted in mice, the cellular mechanisms involved—insulin receptors, digestive enzymes, inflammation, and Kras mutations—are all relevant to humans.
The researchers also noted that the human pancreas exhibits gene expression patterns similar to those observed in the mice in their study, strengthening the translational relevance of their findings.
A Call for Awareness and a New Perspective
Pancreatic cancer remains a devastating disease, largely because it is often diagnosed too late. This research highlights the importance of examining the “pre-history” of the disease—the metabolic state years before a tumor forms.
For the general public, the message is clear: chronic hyperinsulinemia is a silent but critical risk factor. It’s not just about the number on the scale or even blood sugar levels; it’s about the hidden stress of persistently high insulin.
For the medical community, this study reframes the conversation. It suggests that managing hyperinsulinemia should be considered a key strategy in pancreatic cancer prevention, particularly for those with obesity, a family history of the disease, or early signs of metabolic syndrome.
By revealing the direct role of insulin and its receptor in the initiation of pancreatic cancer, this study has opened a new front in the fight against this deadly disease. It transforms our understanding of obesity-related cancer risk from a vague association into a concrete biological pathway—a pathway that, with the right tools and awareness, we may be able to interrupt and ultimately prevent.
Don’t Get Sick!
About Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.
Other articles discussing the problem with high blood sugar. Even in those without diabetes.
- A Perfect Storm: Diabetes and the Rise of Antibiotic Resistance
- Plantar Fasciitis: A Warning Sign Of Future Health Risks
- Trigger Finger and Its Alarming Relationship with High Blood Sugar
- Postprandial Glucose And Kidney Health: The Silent Connection
- High Blood Sugar Effects: Impact On Hair Color And Growth
- High Blood Sugar and Vision: A Guide for Everyone
- High blood sugar damages the arteries and changes the immune system.
- A Tool Box of Strategies to Prevent Blood Sugar Spikes When Eating High Glycemic Index Foods
- A High One hour After-Meal Blood Sugar Test can Lead to Several Deadly Conditions
- A surprising reason why people get heart attacks
- After-meal high blood sugar predicts Atherosclerosis better than Fasting blood sugar and HbA1c
- After-meal blood sugar spikes as a cause of vascular failure
- Veggies Meat Carbohydrate Sequence Prevents After Meal Sugar Spike
- A Healthy Lifestyle is as effective as Voglibose and Nateglinide in Lowering 10-year Cardiac Mortality
- The Shocking Truth About Spike Proteins, Sugar And Inflammation
Reference:
- Zhang, A.M.Y., et al. “Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation.” Cell Metabolism (2023). https://doi.org/10.1016/j.cmet.2023.10.003
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2026 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.